OncRef
Skip to newsletter content
|
mCRPCJuly 2026
0:00 / 2:57
Metastatic Castration Resistant Prostate Cancer — Monthly Compass
Jul 01–31, 2026 • Priority Updates • 3–5 minute read
 
A curated, practice-minded digest of what moved in metastatic castration resistant prostate cancer this month — regulatory signals, clinical development, and the most practice-relevant publications.
Built for oncologists OncRef Curated Oncology Intelligence Layer
metastatic castration resistant prostate cancer updates
Key Highlights
Key Highlights
  • Practice-Changing Updates
    • On July 31, 2026, the FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) with an androgen receptor pathway inhibitor for adults with PSMA‑positive metastatic androgen pathway modulation‑naïve or ‑sensitive prostate cancer based on PSMAddition’s radiographic PFS improvement, with a recommended 7.4 GBq dose every six weeks for up to six cycles or until progression or unacceptable toxicity.
  • Key Clinical Development Updates
    • Telix secured FDA alignment via a successful Type B meeting confirming Part 1 safety suffices to initiate U.S. Part 2 of the ProstACT Global Phase 3 for TLX591‑Tx (177Lu‑rosopatamab tetraxetan) in mCRPC, with agreement on the Part 2 protocol, statistical analysis plan, and safety monitoring, enabling an IND amendment submission pending FDA review.
    • ORIC initiated Himalayas‑1, a global Phase 3 registrational trial of the PRC2/EED inhibitor rinzimetostat plus darolutamide in mCRPC previously treated with abiraterone following End‑of‑Phase 1 interactions that finalized the protocol, with Bayer supplying darolutamide under a clinical collaboration and supply agreement.
  • Key Conference Updates
    • July meetings highlighted momentum toward alpha‑emitting PSMA radiotherapeutics and operational workflows for Pluvicto—including toxicity monitoring and imaging‑led patient selection—pointing to deeper responses and safer delivery beyond current beta emitters.
    • Conference and ASCO coverage emphasized ABBV‑969, a dual PSMA/STEAP1 Topo‑1i ADC showing promising activity and manageable safety in heavily pretreated mCRPC, and the Phase 3 evaluation of pasritamig (KLK2‑targeted T‑cell engager) with docetaxel versus docetaxel alone toward registrational intent.
  • Emerging Themes & Macro-Trends
    • Late‑July CMS 2027 OPPS and PFS proposed rule summaries signaled potential impacts on radioligand therapy reimbursement pathways, and the ASCO Living Guideline v2026.1.4 (July 20) refined sequencing frameworks anchoring real‑world adoption.
    • Strategic imperatives coalesced around investing in PSMA‑alpha platforms, ctDNA/PET analytics, and dual‑antigen ADCs while scaling theranostics operations with supply and quality‑assurance readiness to secure first‑mover advantage.
FDA Approvals/Withdrawals
FDA Approvals/Withdrawals
  • On July 31, 2026, the FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer. This approval was based on the PSMAddition trial, which demonstrated a statistically significant improvement in radiographic progression-free survival. The recommended dose is 7.4 GBq (200 mCi) every six weeks for six doses, or until disease progression or unacceptable toxicity.¹ (read more)
Clinical Development Regulatory Updates
Clinical Development Regulatory Updates
  • Telix Pharmaceuticals reported a successful Type B FDA meeting for TLX591-Tx (177Lu-rosopatamab tetraxetan) in metastatic castration-resistant prostate cancer, with the Agency confirming Part 1 safety suffices to progress Part 2 of the ProstACT Global Phase 3 trial in the U.S. and aligning on the Part 2 protocol, statistical analysis plan, and safety monitoring; Telix said this enables submission of an IND amendment to initiate U.S. Part 2 pending FDA review. (globenewswire.com)¹ (read more)
  • ORIC Pharmaceuticals initiated the Himalayas-1 global Phase 3 registrational trial of the PRC2/EED inhibitor rinzimetostat plus darolutamide in mCRPC previously treated with abiraterone, following End-of-Phase 1 interactions with the FDA and other health authorities that finalized the trial protocol; Bayer will supply darolutamide under a clinical collaboration and supply agreement. (oricpharma.com)² (read more)
Conference
Major Conference Updates
Conference Information
  • 5th Targeted Radiopharmaceuticals Summit US, San Diego, CA, July 21–23, 2026; AHRA 2026 Annual Meeting (session on PSMA-targeted radioligand therapy), San Diego, CA, July 15, 2026; UroToday’s July 2026 ASCO coverage (ASCO Annual Meeting held May 29–June 1, 2026, Chicago, IL); SNMMI press release, Reston, VA, July 16, 2026. (read more)
  • Overall sentiment: July content underscored accelerating innovation in mCRPC across radiotherapeutics, ADCs, and bispecific T‑cell engagers, with growing emphasis on biomarker‑guided selection and operational readiness for broader access. (read more)
  • Theme 1: PSMA-Targeted Radiotherapeutics 2.0 (Alpha shift, dosimetry, implementation)
    • Significance: Momentum toward higher‑LET alpha strategies and more precise dosing/operations points to deeper responses and safer delivery beyond current beta emitters. (read more)
    • Mechanism insights / clinical impact: Multi-stakeholder sessions highlighted alpha‑emitting PSMA therapies gaining traction and practical workflows for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), including toxicity monitoring and imaging‑led patient selection. (read more)
    • Patient populations affected: Post‑ARPI, post‑taxane mCRPC; PSMA‑positive by PET; centers scaling theranostics services in US/EMEA. (read more)
  • Theme 2: Biomarker‑Guided Selection for Radiopharmaceuticals
    • Significance: July data supported ctDNA and imaging biomarkers as decision tools to enrich benefit and monitor resistance, aiming to reduce futile exposure and cost. (read more)
    • Mechanism insights / clinical impact: A noninvasive DNA blood test stratified outcomes with 223Ra in bone‑metastatic mCRPC (associations with TP53/PTEN/cell‑cycle alterations); newsletter coverage spotlighted baseline PSMA PET features predicting 177Lu‑based response—together enabling adaptive treatment and earlier switch at progression. (read more)
    • Patient populations affected: Bone‑predominant mCRPC (223Ra candidates); PSMA‑avid mCRPC considered for 177Lu-PSMA. (read more)
  • Theme 3: ADCs Reimagined to Tackle Antigen Heterogeneity
    • Significance: Dual‑targeting ADCs aim to overcome heterogeneous PSMA/STEAP1 expression and post‑RLT resistance, positioning ADCs as a potential next line after ARPI/taxane/RLT. (read more)
    • Mechanism insights / clinical impact: “ABBV‑969,” a dual PSMA/STEAP1 Topo‑1i ADC, showed promising activity and manageable safety in heavily pretreated mCRPC per July ASCO coverage, supporting continued development. (read more)
    • Patient populations affected: Heavily pretreated mCRPC (including prior taxane and/or PSMA‑RLT), biomarker‑unselected but leveraging dual‑antigen expression. (read more)
  • Theme 4: Bispecific T‑Cell Engagers Move into Phase 3
    • Significance: TCEs are testing head‑to‑head with chemotherapy, signaling a potential immunotherapy foothold in late‑line mCRPC. (read more)
    • Mechanism insights / clinical impact: Pasritamig (JNJ‑78278343), a kallikrein‑2–targeted T‑cell engager, is being evaluated with docetaxel versus docetaxel alone in mCRPC, reflecting confidence in activity and tolerability moving toward registrational intent. (read more)
    • Patient populations affected: Chemo‑eligible mCRPC across KLK2‑expressing disease; global multi‑center settings anticipated. (read more)
  • Significance
    • Expected clinical or translational readouts: Additional ctDNA/radiomics validation in mCRPC radiopharm therapy; expanded early‑phase data for dual‑target ADCs; interim signals from KLK2‑TCE phase 3. (read more)
    • Regulatory or policy implications: Proposed 2027 OPPS and PFS rulemaking (late‑July summaries) could affect RLT reimbursement pathways; ASCO Living Guideline (v2026.1.4; July 20) refines sequencing frameworks anchoring real‑world adoption. (read more)
    • Potential shifts in standard of care: If ADC/TCE efficacy translates in later‑phase trials, post‑ARPI/taxane sequences could diversify beyond RLT/chemo; biomarker‑guided RLT selection may standardize. (read more)
    • Strategic implications: Invest in PSMA‑alpha platforms, ctDNA/PET analytics, and dual‑antigen ADCs; prepare sites for theranostics operations and manage supply/QA to capture first‑mover advantage. (read more)
Publications Related to Approved Drugs
Phase 3
talazoparib
Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial. This post hoc analysis of the TALAPRO-2 trial reconstructed patient data to explore time-dependent treatment effects of talazoparib plus enzalutamide in patients with mCRPC without HRR deficiencies. While not statistically significant, the findings are hypothesis-generating, suggesting potential for delayed overall survival benefits and early radiographic progression-free survival benefits in this specific subgroup. ()
Phase 3
apalutamide, enzalutamide
Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. This matching-adjusted indirect comparison of the ARCHES (enzalutamide) and TITAN (apalutamide) trials suggests broadly similar efficacy between enzalutamide and apalutamide for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The analysis found comparable outcomes for overall survival and time to PSA progression, with no significant differences in radiographic progression-free survival after sensitivity analyses. (, )
New Publications Related to Drugs in Clinical Trial Development
Phase 1
Theranostic Potential of 177Lu-TLX591 with Best Standard-of-Care and 68Ga-PSMA-11 PET for Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the Phase 1 ProstACT SELECT Trial. The ProstACT SELECT trial demonstrated that the radio antibody-drug conjugate 177Lu-TLX591, when combined with standard of care, shows a manageable safety profile and durable tumor retention in mCRPC patients selected via 68Ga-PSMA-11 PET. Notably, this agent resulted in low salivary gland radiation exposure, a key differentiator from small molecule radioligand therapies, supporting its continued development. ()
Phase 2
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial. In the CheckPRO trial for heavily pretreated mCRPC, the addition of stereotactic body radiation therapy (SBRT) to the nivolumab and ipilimumab combination did not improve PSA response rates or overall survival. While the combination of nivolumab and ipilimumab alone showed activity in a fraction of patients, these findings do not support the addition of SBRT and underscore the need for predictive biomarkers for immunotherapy in this setting. ()
PHASE1, PHASE2
Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer. A novel triplet immunotherapy, combining a vaccine (BN-Brachyury), a dual PD-L1/TGF-β inhibitor (bintrafusp alfa), and an IL-15 superagonist (nogapendekin-alfa inbakicept), achieved sustained PSA declines in 29% of patients with mismatch repair proficient CRPC. This multi-pronged strategy, which activates both NK and CD8+ T cells, represents a promising approach for this immunologically "cold" tumor type. ()
Clinical Trials
Clinical Trials Summary
Number of Clinical Trials in metastatic castration resistant prostate cancer updated from 2026-07-01 to 2026-07-31:
Phase 1Phase 1/2Phase 2Phase 2/3Phase 3Phase 4Total
Enrolling by Invitation-------
Not Yet Recruiting11-1--3
Recruiting546-1117
Available-------
Approved for Marketing-------
Active, Not Recruiting327-1114
Completed----112
Total971313336
Phase 1 Clinical Trials within 3 Months of Primary Completion Date:
No phase 1 trials completing within the next three months.
Phase 2 Clinical Trials within 3 Months of Primary Completion Date:
No phase 2 trials completing within the next three months.
Phase 3 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Enzalutamide, : Pembrolizumab NCT03834493 COMPLETED A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) 2026-06-08
Phase 4 Clinical Trials within 3 Months of Primary Completion Date:
DRUGNCTIDStatusClinical Trial NameCompletion Date
Apalutamide, Androgen-deprivation Therapy (ADT) NCT04108208 COMPLETED A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) 2026-06-05
ARPI therapy, Radium-223 dichloride (Xofigo, BAY88-8223) NCT04597125 ACTIVE_NOT_RECRUITING A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of ARPI 2026-10-12
NOTICE: This communication may contain confidential or proprietary information of Oncology Reference, Inc. Data is compiled from publicly available and third-party sources and integrated with proprietary Oncology Reference database mappings, developed and maintained by PhD scientists and advanced AI systems, for organization and analysis. While reasonable efforts are made to ensure accuracy and timeliness, Oncology Reference, Inc. makes no representation or warranty, express or implied, regarding accuracy, completeness, or fitness for a particular purpose. Information may contain errors, omissions, or be subject to change without notice. This material is for informational purposes only and is not medical advice, regulatory guidance, investment advice, or a substitute for professional judgment. Users must independently verify all information.

Oncology Reference, Inc. and its affiliates disclaim all liability for any loss or damage arising from use of or reliance on this information. By using this information, you agree that disputes will be governed by Delaware law and resolved by binding arbitration in Delaware.
California residents waive California Civil Code § 1542. All trademarks are the property of their respective owners.
© 2025 Oncology Reference, Inc. All rights reserved.

CONFIDENTIALITY NOTICE: If you are not the intended recipient, please notify the sender, delete this message, and refrain from using or disclosing its contents.